TITLE

02. Characterising cardiovascular safety profile of muscarinic antagonist, ipratropium

AUTHOR(S)
Simmons, K.; Khan, J.; Hussain, A.; Maddock, H. L.
PUB. DATE
January 2011
SOURCE
Heart;Jan2011, Vol. 97 Issue 1, pe1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Chronic Obstructive Pulmonary Disease (COPD) is a disease characterised by inflammation of the airways which accounts for the fourth highest cause of global death. The functional role of Muscarinic receptor antagonists such as Ipratropium Bromide (Atrovent) and Tiotropium Bromide (Spiriva) has been shown to successfully improve pulmonary function in COPD patients. Recent studies have associated an increased risk of cardiovascular events in COPD patients currently receiving treatment with Muscarinic receptor antagonists such as Ipratropium (Ogale et al, 2010). The study aimed to investigate the effects of Ipratropium on the myocardium subjected to ischaemia-reperfusion (I/R). Langendorff hearts were subjected to control or I/R in the absence or presence of Ipratropium (1⇔…nM, 10⇔…nM, or 100⇔…nM). Hearts underwent triphenyl tetrazolium staining for infarct size assessment. In further studies cardiac myocytes were isolated and exposed to simulated I/R in the absence or presence of Ipratropium (1⇔…fM-"1⇔…mM) and cellular injury was subsequently determined by measurement of live/death ratio and apoptosis using flow cytometry. Administration of Ipratropium (10⇔…nM or 100⇔…nM) throughout reperfusion significantly increased infarct size to risk ratio (%) compared with non-treated controls (62±2%, 74±4% vs 52±3%, control p<0.01, respectively). In isolated myocyte experiments, Ipratopium-treated groups were observed to significantly increase apoptosis and cell death compared to non-treated controls. This is the first pre-clinical study to show that Ipratropium significantly increases myocardial injury when administered during I/R. Further studies are being investigated to determine the mechanism of action of the cardiovascular events associated with certain bronchodilators.
ACCESSION #
60944909

 

Related Articles

  • Ipratropium Bromide-Mediated Myocardial Injury in In Vitro Models of Myocardial Ischaemia/Reperfusion. Harvey, Kate L.; Hussain, Afthab; Maddock, Helen L. // Toxicological Sciences;Apr2014, Vol. 138 Issue 2, p457 

    Ipratropium bromide, a nonselective muscarinic antagonist, is widely prescribed for the treatment of chronic obstructive pulmonary disease (COPD). Analyses of COPD patients, with underlying ischaemic heart disease, receiving anticholinergics, have indicated increased risk of severity and...

  • Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD. D'Urzo, Anthony // Therapeutics & Clinical Risk Management;2013, Vol. 9, p341 

    Progressive airflow limitation is a hallmark feature of chronic obstructive pulmonary disease (COPD) that ultimately leads to breathlessness, impaired quality of life, and reduced exercise capacity. Pharmacotherapy is used in patients with COPD to prevent and control symptoms, reduce both the...

  • Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. D'Urzo, Anthony; Ferguson, Gary T.; van Noord, Jan A.; Hirata, Kazuto; Martin, Carmen; Horton, Rachael; Yimeng Lu; Banerji, Donald; Overend, Tim // Respiratory Research;Dec2011, Vol. 12 Issue 12, p1 

    Background: NVA237 is a once-daily dry-powder formulation of the long-acting muscarinic antagonist glycopyrronium bromide in development for the treatment of chronic obstructive pulmonary disease (COPD). The glycopyrronium bromide in COPD airways clinical study 1 (GLOW1) evaluated the efficacy,...

  • Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease. Zhong, Jun; Roth, Michael // Therapeutics & Clinical Risk Management;2014, Vol. 10, p449 

    Chronic obstructive pulmonary disease (COPD) is increasing worldwide and is predicted to become the third most frequent cause of death by 2030. Muscarinic receptor antagonists, alone or in combination with long-acting β2-agonists, are frequently used for COPD therapy. Aclidinium bromide is a...

  • Once-daily bronchodilator treatment for COPD.  // British Journal of Hospital Medicine (17508460);Nov2014, Vol. 75 Issue 11, p609 

    The article reports on the launch of Incruse Ellipta's once-daily bronchodilator for the management of symptoms of chronic obstructive pulmonary disease (COPD).

  • Forest and Almirall Announce Submission of New Drug Application for Aclidinium Bromide for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).  // Biomedical Market Newsletter;7/5/2011, p249 

    The article reports on the new drug application (NDA) for aclidinium bromide submitted by Almirall SA and Forest Laboratories Inc. to the U.S. Food and Drug Administration (FDA). It states that aclidinium bromide is a long-acting inhaled antimuscarinic drug for the treatment of chronic...

  • Forest Labs and Almirall Announce FDA has Extended Review Period for Aclidinium Bromide.  // Biomedical Market Newsletter;4/1/2012, Vol. 21, p1 

    The article reports on the announcement by Forest Laboratories Inc. and Almirall SA regarding the extension of review period for aclidinium bromide by the Food & Drug Administration of the U.S. Aclidinium bromide is an antimuscarinic agent that is required for the treatment of Chronic...

  • Ipratropium and cardiovascular events in COPD.  // Internal Medicine Alert;3/15/2010, Vol. 32 Issue 5, p39 

    The article discusses the risk on the use of metered-dose inhaler administration of ipratropium (IPR) among patients with chronic obstructive pulmonary disease (COPD).

  • Ipratropium and CV events in COPD.  // Critical Care Alert;Apr2010 Clinical Briefs, p7 

    The article reports on the 29% higher risk in chronic obstructive pulmonary disease (COPD) patients treated with Ipratropioum (IPR) than comparators according to a cohort study by Ogale and colleagues.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics